P. Clarke

发表

Gene expression microarray technologies in the development of new therapeutic agents.

P. Workman, P. Clarke, R. T. te Poele, 2004, European journal of cancer.

Discovery of small molecule cancer drugs: Successes, challenges and opportunities

P. Workman, P. Clarke, S. Hoelder, 2012, Molecular oncology.

Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance

B. Al-Lazikani, P. Workman, P. Clarke, 2012, Clinical pharmacology and therapeutics.

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

J. Ware, J. Spoerke, P. Workman, 2014, Clinical Cancer Research.

Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1.

Paul Workman, Rainer Cramer, Chrisostomos Prodromou, 2002, Molecular cell.

A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease

Gary Box, Julian Blagg, Paul Workman, 2015, Nature chemical biology.

Evolution of kinase polypharmacology across HSP90 drug discovery

B. Al-Lazikani, P. Workman, A. Antolin, 2020, bioRxiv.

Sensitization of (colon) cancer cells to death receptor related therapies

B. Zhivotovsky, P. Workman, J. Martinou, 2012, Cancer biology & therapy.

Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

Paul Workman, Rainer Cramer, Marketa Zvelebil, 2007, Cancer research.

Surprising specificity of PKR binding to delta agent genomic RNA.

M. Mathews, P. Clarke, H. Robertson, 1997, RNA.

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor

Nathan Brown, Julian Blagg, Paul Workman, 2018, Molecular oncology.

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .

Gary Box, Paul Workman, Christian Wiesmann, 2008, Journal of medicinal chemistry.

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.

D. Cunningham, P. Clarke, F. Raynaud, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overexpression of EZH 2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

P. Workman, P. Clarke, Z. Walters, 2017 .

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

Caleb K. Stein, G. Morgan, P. L. Bergsagel, 2017, Blood Cancer Journal.

2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19

F. Rohdich, P. Workman, D. Musil, 2016, ACS medicinal chemistry letters.

Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX

P. Workman, P. Clarke, M. Valenti, 2013, Oncotarget.

Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.

P. Workman, P. Clarke, M. Powers, 2008, Cancer cell.

Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas.

H. J. Schneider, A. Norman, D. Cunningham, 1997, British Journal of Cancer.

Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma

D. Cunningham, P. Clarke, P. Ross, 2001, Gut.

The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

M. Gore, P. Workman, U. Banerji, 2012, Molecular Cancer Therapeutics.

Native size exclusion chromatography-based mass spectrometry (SEC-MS) identifies novel components of the Heat Shock Protein 90-dependent proteome

A. Lamond, S. Andrews, P. Workman, 2022, bioRxiv.

The kinase polypharmacology landscape of clinical PARP inhibitors

B. Al-Lazikani, P. Workman, A. Antolin, 2020, Scientific Reports.

The off-target kinase landscape of clinical PARP inhibitors

B. Al-Lazikani, P. Workman, A. Antolin, 2019, bioRxiv.

De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of the Mediator Complex, Cause a Syndromic Developmental Disorder

E. van Binsbergen, S. Twigg, A. Wilkie, 2019, American journal of human genetics.

The Deciphering Developmental Disorders Study (2019). De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of the Mediator Complex, Cause a Syndromic Developmental Disorder. American Journal of Human Genetics 104 (4),

M. V. Dooren, S. Twigg, A. Wilkie, 2019 .

Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins

L. Pearl, P. Workman, P. Clarke, 2013, Oncogene.

The expanding proteome of the molecular chaperone HSP90

P. Workman, P. Clarke, Rahul S. Samant, 2012, Cell cycle.

Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.

P. Workman, K. Boxall, P. Clarke, 2005, Assay and drug development technologies.

HSF1 in Translation.

P. Workman, P. Clarke, E. de Billy, 2013, Cancer cell.

Molecular Medicine in Practice The Association of PI 3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

M. Gore, J. Bono, P. Workman, 2012 .

The Association of PI 3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer

M. Gore, J. Bono, P. Workman, 2012 .

Hsp90-Dependent Activation of Protein Kinases Is Regulated by Chaperone-Targeted Dephosphorylation of Cdc37

L. Pearl, P. Piper, L. Neckers, 2008, Molecular cell.

Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes

Sarah A Martin, P. Clarke, P. Cutillas, 2021, Cell Death & Disease.

Modulation of Biliary Cancer Chemo‐Resistance Through MicroRNA‐Mediated Rewiring of the Expansion of CD133+ Cells

L. Cascione, M. Fassan, A. Scarpa, 2019, Hepatology.

Loss of Spindly sensitizes EML4-ALK v3 lung cancer cells to HSP90 inhibitors

R. Doebele, P. Workman, A. Le, 2022, bioRxiv.

The Phosphoinositide 3-Kinase Inhibitor PI-103 Downregulates Choline Kinase α Leading to Phosphocholine and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy

M. Leach, P. Workman, P. Clarke, 2010 .

Molecular profiling and combinatorial activity of CCT068127

M. Noble, P. Workman, S. Whittaker, 2017 .

First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trial

I. Judson, D. Cunningham, P. Clarke, 1997 .

ES-285, a novel marine anticancer agent: Investigation of mechanism of action using gene expression microarrays

P. Workman, P. Clarke, R. Baird, 2005 .

Analysis of tumour gene expression following chemotherapeutic treatment of patients with bowel cancer

Paul Workman, David Cunningham, P. Workman, 1999, Nature Genetics.

Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling.

Paul Workman, David Cunningham, D. Tait, 2003, Cancer research.

Assays for HSP90 and inhibitors.

L. Pearl, P. Workman, M. Walton, 2003, Methods in molecular medicine.

Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo

P. Workman, M. Walton, P. Clarke, 2004, British Journal of Cancer.

R-loop editing by DNA cytosine deaminase APOBEC3B determines the activity of estrogen receptor enhancers

B. Al-Lazikani, O. Rossanese, P. Workman, 2022, bioRxiv.

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

M. Waterfield, P. Workman, P. Parker, 2007, Cancer research.

Corrigendum: Drugging the PI3 kinome

P. Workman, P. Clarke, F. Raynaud, 2006, Nature Biotechnology.

Epstein-Barr virus gene expression in interferon-treated cells. Implications for the regulation of protein synthesis and the antiviral state.

M. Clemens, P. Clarke, J. Arrand, 1990, Biochimica et biophysica acta.

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

P. Workman, Irina S. Chuckowree, P. Clarke, 2009, Molecular Cancer Therapeutics.

Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study.

D C Linch, K. Maclennan, D. Cunningham, 1996, Blood.

Native Size-Exclusion Chromatography–Based Mass Spectrometry Reveals New Components of the Early Heat Shock Protein 90 Inhibition Response Among Limited Global Changes

A. Lamond, S. Andrews, P. Workman, 2022, Molecular & cellular proteomics : MCP.

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

Julian Blagg, Paul Workman, Florence I. Raynaud, 2016, Journal of medicinal chemistry.

Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements.

P. Workman, P. Clarke, F. Raynaud, 2011, Bioorganic & medicinal chemistry.

CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells

P. Workman, Rebecca F Rogers, M. Walton, 2020, Cancer Research.

Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.

Julian Blagg, Djordje Musil, Paul Czodrowski, 2016, Journal of medicinal chemistry.

The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design

R. V. van Montfort, P. Workman, R. Griffin, 2013, Oncotarget.

Inhibitors of cyclin‐dependent kinases as cancer therapeutics

P. Workman, S. Whittaker, P. Clarke, 2017, Pharmacology & therapeutics.

Personalized medicine: patient-predictive panel power.

Paul Workman, Bissan Al-Lazikani, B. Al-Lazikani, 2012, Cancer cell.

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

Charles Y. Lin, J. Bradner, N. Gray, 2020, The Journal of clinical investigation.

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone

P. Workman, I. Judson, M. Walton, 2000, Oncogene.

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Andrea Sottoriva, Nina Tunariu, Paul Workman, 2018, Science.

Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

Paul Workman, R. V. van Montfort, P. Workman, 2010, Cancer research.

Correlation of overall survival with gene expression profiles in a prospective study of resectable esophageal cancer.

A. Norman, I. Giddings, P. Workman, 2011, Clinical colorectal cancer.

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

J. Verweij, P. Workman, I. Judson, 2009, Molecular Cancer Therapeutics.

Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells

M O Leach, M. Leach, P. Clarke, 2002, British Journal of Cancer.

Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

이석호, 황수찬, T. Walsh, 2001, British Journal of Cancer.

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

D. Cunningham, P. Clarke, P. Ross, 1997, The Lancet.

Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy

Chris Jones, M. Leach, P. Workman, 2017, Oncotarget.

In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells

Chris Jones, M. Leach, P. Workman, 2017, PloS one.

Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma

Paul Workman, Lynn Bjerke, Melanie Valenti, 2009, Cell cycle.

Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential.

R. Wooster, P. Workman, R. Wooster, 2001, Biochemical pharmacology.

Small-molecule targeting of brachyury transcription factor addiction in chordoma

Christopher J. Ott, Ann E. Sizemore, Charles Y. Lin, 2019, Nature Medicine.

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer

P. Workman, D. Zheleva, D. Blake, 2020, PloS one.

Binding of Epstein-Barr virus small RNA EBER-1 to the double-stranded RNA-activated protein kinase DAI.

K. Hilse, M. Clemens, P. Clarke, 1991, Nucleic acids research.

Silencing the cochaperone CDC37 destabilises kinase clients and sensitises cancer cells to HSP90 inhibitors

P. Workman, P. Clarke, Jennifer R. Smith, 2008, Oncogene.

Lactate and Choline Metabolites Detected In Vitro by Nuclear Magnetic Resonance Spectroscopy Are Potential Metabolic Biomarkers for PI3K Inhibition in Pediatric Glioblastoma

Chris Jones, M. Leach, P. Workman, 2014, PloS one.

Drugging PI3K in cancer: refining targets and therapeutic strategies

Paul Workman, Lynn Bjerke, Timothy A Yap, 2015, Current opinion in pharmacology.

Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen

F. Rohdich, T. Dale, P. Workman, 2015, Journal of medicinal chemistry.

Development of a novel prokaryotic two-hybrid system for the detection and analysis of protein-protein interactions in vivo

P. Clarke, 2000 .

Death by chaperone: HSP90, HSP70 or both?

P. Workman, P. Clarke, M. Powers, 2009, Cell cycle.

Innovative cancer drug targets: genomics, transcriptomics and clinomics

P. Workman, P. Clarke, 2001, Expert opinion on pharmacotherapy.

Ultrastructural localization of BHRF1: an Epstein-Barr virus gene product which has homology with bcl-2.

T. Hickish, P. Clarke, M. Hill, 1994, Cancer research.

A PI3K- and GTPase-independent Rac1-mTOR mechanism mediates MET-driven anchorage-independent cell growth but not migration

P. Clarke, Chi Zhang, C. Joffre, 2020, Science Signaling.

A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer

D. Root, F. Piccioni, S. Whittaker, 2020, Molecular Cancer Therapeutics.

Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.

P. Workman, P. Clarke, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interactions between the double-stranded RNA binding motif and RNA: definition of the binding site for the interferon-induced protein kinase DAI (PKR) on adenovirus VA RNA.

M. Mathews, P. Clarke, Michael B. Mathews, 1995, RNA.

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

A. Norman, D. Cunningham, P. Clarke, 1998, Journal of the National Cancer Institute.

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors

S. Robinson, P. Workman, W. Weiss, 2016, Oncotarget.

Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

P. Workman, P. Clarke, I. Hostein, 2001, Cancer research.

Cytostasis and Apoptosis 17-Allylamino-17-demethoxygeldanamycin Results in Inhibition of Signal Transduction by the Hsp 90 Inhibitor Updated Version

P. Workman, P. Clarke, I. Hostein, 2001 .

RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses

P. Workman, P. Clarke, J. D. de Bono, 2017, British Journal of Cancer.

Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors

P. Workman, P. Clarke, F. Raynaud, 2011, Current medicinal chemistry.

Drugging the PI3 kinome

P. Workman, P. Clarke, F. Raynaud, 2006, Nature Biotechnology.

Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology.

Paul Workman, Bissan Al-Lazikani, B. Al-Lazikani, 2013, Current opinion in pharmacology.

K-ras mutations in patients with early colorectal cancers

A. Norman, D. Cunningham, P. Clarke, 1997, Gut.

Resisting targeted therapy: fifty ways to leave your EGFR.

P. Workman, P. Clarke, 2011, Cancer Cell.

Mutant K-ras2 in serum

A. Norman, B. Iacopetta, D. Cunningham, 2003, Gut.

Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotides.

P. Workman, D. Cunningham, P. Clarke, 2001, Molecular cancer therapeutics.

Translational control by the Epstein-Barr virus small RNA EBER-1. Reversal of the double-stranded RNA-induced inhibition of protein synthesis in reticulocyte lysates.

M. Clemens, P. Clarke, N. Sharp, 1990, European journal of biochemistry.

In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors.

L. Pearl, P. Workman, R. Marais, 2007, Cancer research.

Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.

M. Dowsett, P. Workman, A. Howes, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signalling

P. Workman, P. Clarke, F. Davies, 2018, Cellular signalling.

Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective.

P. Workman, P. Clarke, Alison Maloney, 2003, Current cancer drug targets.

E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells

P. Workman, P. Clarke, Rahul S. Samant, 2014, Proceedings of the National Academy of Sciences.

ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system.

Paul Workman, Chrisostomos Prodromou, Laurence H Pearl, 2013, Nature chemical biology.

Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer

Paul Workman, Rosemary Burke, R. V. van Montfort, 2019, Oncogene.

The kinase polypharmacology landscape of clinical PARP inhibitors

B. Al-Lazikani, P. Workman, A. Antolin, 2020, Scientific Reports.

Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766)

P. Workman, P. Clarke, J. Caldwell, 2017, Journal of medicinal chemistry.

Blocking the survival of the nastiest by HSP90 inhibition

B. Al-Lazikani, P. Workman, P. Clarke, 2016, Oncotarget.

MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma

C. Croce, P. Gasparini, L. Cascione, 2017, Gastroenterology.

MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma

C. Croce, P. Gasparini, L. Cascione, 2017, Gastroenterology.

Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases

S. Czasch, F. Rohdich, T. Dale, 2016, eLife.

Expression of genes for the Epstein-Barr virus small RNAs EBER-1 and EBER-2 in Daudi Burkitt's lymphoma cells: effects of interferon treatment.

M. Clemens, P. Clarke, N. Sharp, 1992, The Journal of general virology.

Discovery and validation of biomarkers to support clinical development of NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor

P. Workman, P. Clarke, M. Valenti, 2022, European Journal of Cancer.

The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma

R. Houlston, P. Workman, P. Clarke, 2017 .

Combining TRAIL with PI3 Kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling

P. Workman, P. Clarke, M. Valenti, 2013, Oncotarget.

Structural features of adenovirus 2 virus-associated RNA required for binding to the protein kinase DAI.

M. Mathews, P. Clarke, T. Pe’ery, 1994, Nucleic acids research.

The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.

M. Leach, P. Workman, P. Clarke, 2010, Cancer research.

Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases

Paul Workman, Bissan Al-Lazikani, Sibylle Mittnacht, 2019, bioRxiv.

HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies

P. Workman, P. Clarke, Alan T. Henley, 2023, Journal of medicinal chemistry.

Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis

J. Griffiths, M. Leach, D. Cunningham, 1999, British Journal of Cancer.

Resisting targeted therapy: fifty ways to leave your EGFR.

P. Workman, P. Clarke, 2011, Cancer cell.

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

P. Workman, Irina S. Chuckowree, P. Clarke, 2009, Molecular Cancer Therapeutics.

ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system.

L. Pearl, P. Workman, P. Clarke, 2013, Nature chemical biology.

Corrigendum: ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system

L. Pearl, P. Workman, P. Clarke, 2013 .